Plamotamab is a monoclonal antibody commercialized by Xencor, with a leading Phase I program in Relapsed Chronic Lymphocytic Leukemia (CLL);Refractory Chronic Lymphocytic Leukemia (CLL). According to Globaldata, it is involved in 7 clinical trials, of which 4 are ongoing, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Plamotamab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Plamotamab is expected to reach an annual total of $221 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Plamotamab Overview
Plamotamab (XmAb-13676) is under development for the treatment of B cell malignancies such as Richter's transformation, follicular lymphoma, relapsed and refractory Chronic Lymphocytic Leukemia, Marginal Zone B-Cell Lymphoma, multi-drug resistant rheumatoid arthritis and non B-cell chronic lymphocytic leukemia. It is administered intravenously. The drug candidate is a bi-specific monoclonal antibody that targets tumor antigen binding domain CD20 and cytotoxic T-cell CD3 binding domain. The drug candidate development is based on XmAb bi-specific antibody engineering technology.
It was also under development for the treatment of relapsed/refractory diffuse large B-cell lymphoma, Waldenstrom macroglobulinemia, splenic marginal zone B-Cell Lymphoma, extranodal marginal zone B-Cell Lymphoma, mantle cell lymphoma and nodal marginal zone B-Cell Lymphoma.
Xencor Overview
Xencor is a clinical-stage biopharmaceutical company that discovers and develops engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Its other pipeline includes XmAb306/RO7310729, XmAb968 and XmAb662 (IL12-Fc), among others. Xencor’s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Xencor is headquartered in Monrovia, California, the US.
The company reported revenues of (US Dollars) US$168.3 million for the fiscal year ended December 2023 (FY2023), an increase of 2.3% over FY2022. The operating loss of the company was US$138.6 million in FY2023, compared to an operating loss of US$82.6 million in FY2022. The net loss of the company was US$126.1 million in FY2023, compared to a net loss of US$55.2 million in FY2022.
The company reported revenues of US$17 million for the second quarter ended June 2024, an increase of 32.4% over the previous quarter.
For a complete picture of Plamotamab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.